Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

Mallinckrodt plc. (12/8/17). "Press Release: Mallinckrodt to Present at 36th Annual J.P. Morgan Healthcare Conference". Staines-upon-Thames.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation Mallinckrodt plc (NYSE: MNK)
  Group Mallinckrodt (Group)
  Organisation 2 J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 36th Annual Healthcare Conference 2018 San Francisco
  Product 2 pharmaceutical
Index term Index term Mallinckrodt–JPMorgan Chase: investor conference, 201801 supply service Mallinckrodt presents at JP Morgan Healthcare Conference 2018
Persons Person Trudeau, Mark (Mallinckrodt 201712 CEO)
  Person 2 Harbaugh, Matthew (Mallinckrodt 201712 CFO)

Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Monday, Jan. 8, 2018, at the 36th Annual J.P. Morgan Healthcare Conference, which takes place at the Westin St. Francis on Union Square, 335 Powell St., San Francisco.

Mark Trudeau, President and Chief Executive Officer, and Matthew Harbaugh, Executive Vice President and Chief Financial Officer, will represent the company with a presentation at 7:30 a.m. Pacific time, followed by a question-and-answer session from 8 a.m. to 8:25 a.m.

Individuals who cannot attend the meeting in person can find webcast information at: A replay will also be available following the meeting.


Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.


Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO

Daniel J. Speciale, CPA
Director, Investor Relations

Rhonda Sciarra
Senior Communications Manager

Meredith Fischer
Chief Public Affairs Officer

Record changed: 2018-01-09


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Mallinckrodt (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top